Pfimex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
- Paid Up Capital ₹ 13.72 Cr
- Company Age 38 Year, 10 Months
- Last Filing with ROC 31 Mar 2011
- Open Charges ₹ 0.14 M
About Pfimex Pharmaceuticals
Pfimex Pharmaceuticals Limited (PPL) is a Public Limited Indian Non-Government Company incorporated in India on 02 April 1986 and has a history of 38 years and ten months. Its registered office is in Na, Andhra Pradesh.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2011. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 13.72 Cr.
The company currently has active open charges totaling ₹0.14 M.
Girish Bhandari, Niranjan Gokhale, Ranjana Bhandari, and One other member serve as directors at the Company.
Company Details
- Location Na, Andhra Pradesh
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
L24231AP1986PLC006339
- Company No.
006339
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Apr 1986
- Date of AGM
30 Jun 2011
- Date of Balance Sheet
31 Mar 2011
- Listing Status
Listed
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Pfimex Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Purav Bhandari  | Director | 13-Jul-2009 | Current |
| Girish Bhandari | Director | 02-Apr-1986 | Current |
| Niranjan Gokhale | Director | 29-Mar-1997 | Current |
| Ranjana Bhandari | Director | 07-Oct-2011 | Current |
Financial Performance of Pfimex Pharmaceuticals.
Enhance accessibility to Pfimex Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Pfimex Pharmaceuticals?
Unlock access to Pfimex Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.01 Cr
₹0
Charges Breakdown by Lending Institutions
- M/S. Dcl Finance Ltd : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Oct 1987 | M/S. Dcl Finance Ltd | ₹0.14 M | Open |
How Many Employees Work at Pfimex Pharmaceuticals?
Unlock and access historical data on people associated with Pfimex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pfimex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pfimex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.